Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as
maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic
hematopoietic cell transplant (HCT).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute